Olcegepant - CAS:204697-65-4 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	Olcegepant
英文名称:	Olcegepant
别名:	N-[2-[5-氨基-1(S)-[4-(4-吡啶基)哌嗪-1-甲酰基]戊基氨基]-1(R)-(3,5-二溴-4-羟基苄基)-2-氧代乙基]-4-(2-氧代-1,2,3,4-四氢喹唑啉-3-基)哌啶-1-甲酰胺 BIBN-4096; BIBN 4096BS
CAS No:	204697-65-4	分子式:	C₃₈H₄₇Br₂N₉O₅	分子量:	869.65
CAS No:	204697-65-4
分子式:	C₃₈H₄₇Br₂N₉O₅
分子量:	869.65

安全技术说明书(PDF) MSDS(PDF) 点击下载产品说明书(PDF)

O10260 Olcegepant ≥98% (psaitong)

相关产品

包装规格：

2mg in glass bottle

溶解性：

溶于DMSO（≥50mg/mL）

产品描述：

基本信息

产品编号：	O10260
产品名称：	Olcegepant
CAS:	204697-65-4	储存条件	粉末	-20℃	四年

分子式：	C38H47Br2N9O5		溶于液体	-80℃	6个月
分子量：	869.65			-20℃	1个月
化学名：	N-[(2R)-1-[[(2S)-6-amino-1-oxo-1-(4-pyridin-4-ylpiperazin-1-yl)hexan-2-yl]amino]-3-(3,5-dibromo-4-hydroxyphenyl)-1-oxopropan-2-yl]-4-(2-oxo-1,4-dihydroquinazolin-3-yl)piperidine-1-carboxamide
Solubility (25°C)：
体外:	DMSO
	Ethanol
	Water
体内(现配现用):
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	1.1499mL	5.7494mL	11.4989mL
5mM	0.2300mL	1.1499mL	2.2998mL
10mM	0.1150mL	0.5749mL	1.1499mL

生物活性

产品描述	一种有效和选择性的降钙素基因相关肽1 (CGRP1) 受体拮抗剂，IC50 和 Ki 分别为0.03nM，14.4pM。
靶点	IC50:0.03nM (CGRP1) Ki:14.4pM (hCGRP)
体外研究	Olcegepant possesses higher affinity for the human CGRP receptor than the endogenous ligand CGRP and 150-fold higher affinity compared to the peptidic antagonist CGRP8-37.Olcegepant reverses CGRP-mediated vasodilation in human cerebral vessels and inhibits neurogenic vasodilation in a surrogate animal model of migraine pathophysiology.Olcegepant (BIBN4096BS) is extremely potent at primate CGRP receptors exhibiting an affinity (Ki) for human CGRP receptors of 14.4±6.3 (n=4)pM.Several lines of evidence suggest that a calcitonin-gene related peptide (CGRP) receptor antagonist may serve as a novel abortive migraine treatment.Olcegepant (BIBN4096BS) exhibits competitive antagonism at the CGRP receptor present in SK-N-MC cells.Isolated human cerebral,coronary,and omental arteries are studied with a sensitive myograph technique.CGRP induces a concentration-dependent relaxation that is antagonized by Olcegepant in a competitive manner.
体内研究	Olcegepant (BIBN4096BS) in doses between 1 and 30μg/kg (i.v.) inhibits the effects of CGRP,released by stimulation of the trigeminal ganglion,on facial blood flow in marmoset monkeys.Pre-treatment with Olcegepant (900μg/kg) inhibits the capsaicin-induced expression of Fos throughout the spinal trigeminal nucleus by 57%.In contrast,the expression of phosphorylated extracellular signal-regulated kinase in the trigeminal ganglion is not changed by Olcegepant pre-treatment.Olcegepant (0.3 to 0.9mg/kg,i.v.) markedly reduces mechanical allodynia in CCI-ION rats.Olcegepant (0.6mg/kg,i.v.) significantly reduces the number of c-Fos immunolabeled cells in spinal nucleus of the trigeminal nerve and upregulation of ATF3 transcript (a marker of neuron injury) but not that of interleukin-6 in trigeminal ganglion of CCI-ION rats.

推荐实验方法(仅供参考)

激酶实验：

125I-hCGRP is used as the radioligand.The incubation buffer contained (in mM):Tris 50,NaCl 150,MgCl25 and EDTA 1,(ethylene diamine tetra-acetic acid) pH 7.4.Membrane homogenates are incubated for 180 min at room temperature with 50pM 125I-hCGRP and increasing concentrations of Olcegepant (BIBN4096BS).The incubation is terminated by filtration through GF/B glass fibre filters using a cell harvester.The protein-bound radioactivity is determined in a gamma counter.The nonspecific binding is defined as radioactivity bound in the presence of 1μM CGRP.The IC50 values are obtained by non-linear regression analysis on the basis of a one binding site model .

细胞实验:

Cells are washed with phosphate-buffered saline then pre-incubated with 300μM isobutylmethylxanthine in serum-free MEM for 30 min at 37℃ α-CGRP-(S-37) or Olcegepant (BIBN4096BS) is added and the cells are incubated for 10 min before the addition of CGRP.The incubation is continued for another 15 min,then the cells are washed with PBS and processed for cAMP determination.Maximal stimulation over basal is defined by using 100nM CGRP.Dose–response curves are generated by using Prism.

动物实验:

Rats are treated acutely with Olcegepant (0.3,0.6,and 0.9mg/kg,intravenously [i.v.] in a tail vein),GR-85548A (0.1 and 0.3mg/kg subcutaneously [s.c.]),or their respective vehicle.For combined treatment,Olcegepant (0.3mg/kg,i.v.) is administered 30 minutes before GR-85548A (0.1mg/kg,s.c.).The doses and routes of administration are based on previous reports.For subchronic treatment,CCI-ION and sham-operated rats are injected twice per day for 4 days (at 10am and 6pm) with Olcegepant (0.6mg/kg,i.v.) or its vehicle,starting on the 15th day after ligature.A further injection of Olcegepant (0.6mg/kg,i.v.) or vehicle is performed at 10am the subsequent day (19th day after ligature),just before von Frey filament testing.

保存条件：

-20℃

UN码：

HazardClass：

危害声明：

安全说明：

搜索质检报告(COA)

参考文献 & 客户发表文献

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量 =

浓度 *

体积 *

分子量

*选择对应的单位 *空出希望得到的变量，填写另外两个变量

用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入输出 )

* = *

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

摩尔浓度计算公式

稀释公式

连续稀释计算器方程

连续稀释

计算结果